氟维司群联合卡匹色替对比安慰剂用于芳香化酶抑制剂治疗后复发或进展的转移性雌激素受体阳性HER2阴性乳腺癌(FAKTION):随机2期试验的总生存、更新无进展生存及扩展生物标志物分析
FAKTION是一项随机、多中心、双盲、安慰剂对照2期试验,纳入140例芳香化酶抑制剂抵抗的ER阳性HER2阴性晚期乳腺癌绝经后女性,比较氟维司群联合卡匹色替与联合安慰剂的疗效。更新分析显示,卡匹色替组中位无进展生存10.3个月 vs 安慰剂组4.8个月(校正HR 0.56,95%CI 0.38-0.81,双侧p=0.0023),中位总生存29.3个月 vs 23.4个月(校正HR 0.66,95%CI 0.45-0.97,双侧p=0.035)。扩展生物标志物分析提示卡匹色替主要获益于PI3K/AKT/PTEN通路改变的肿瘤患者。
要点
- 卡匹色替联合氟维司群较安慰剂延长中位无进展生存(10.3 vs 4.8个月,校正HR 0.56)和中位总生存(29.3 vs 23.4个月,校正HR 0.66)。
- 扩展通路改变亚组中,卡匹色替组中位无进展生存12.8个月 vs 安慰剂组4.6个月(校正HR 0.44),中位总生存38.9个月 vs 20.0个月(校正HR 0.46)。
- 扩展通路未改变亚组中,卡匹色替与安慰剂的无进展生存和总生存均无统计学显著差异。
核心结论
- 更新的FAKTION数据显示,在氟维司群基础上加用卡匹色替可延长芳香化酶抑制剂抵抗的ER阳性HER2阴性晚期乳腺癌参与者的生存。
- 扩展生物标志物检测提示卡匹色替主要获益于PI3K/AKT/PTEN通路改变的肿瘤患者。
- 需要3期数据来证实这些结果,包括FAKTION试验未纳入的既往CDK4/6抑制剂暴露患者。
研究设计与样本
- 随机、多中心、双盲、安慰剂对照2期试验,在英国19家医院招募绝经后成年女性(≥18岁),ER阳性、HER2阴性、转移性或局部晚期不可手术乳腺癌,ECOG体能状态0-2,芳香化酶抑制剂治疗后复发或进展。
- 2015年3月16日至2018年3月6日筛查183例,140例(77%)随机1:1分配至氟维司群联合卡匹色替组(n=69)或氟维司群联合安慰剂组(n=71)。
- 治疗方案:肌注氟维司群500 mg(第1天)每28天一次(第1周期第15天加500 mg负荷剂量),联合口服卡匹色替400 mg或匹配安慰剂,每日两次,间歇每周方案(用药4天停3天),从第1周期第15天开始。
- 主要终点为意向治疗人群的无进展生存;本文报告的次要终点为意向治疗人群的总生存和安全性,以及扩展检测 panel(含二代测序)识别的肿瘤PI3K/AKT/PTEN通路状态对治疗的影响。
- 数据截止2021年11月25日,卡匹色替组中位随访58.5个月(IQR 45.9-64.1),安慰剂组62.3个月(IQR 62.1-70.3)。
主要发现
- 更新中位无进展生存:卡匹色替组10.3个月(95%CI 5.0-13.4) vs 安慰剂组4.8个月(95%CI 3.1-7.9),校正HR 0.56(95%CI 0.38-0.81),双侧p=0.0023。
- 中位总生存:卡匹色替组29.3个月(95%CI 23.7-39.0) vs 安慰剂组23.4个月(95%CI 18.7-32.7),校正HR 0.66(95%CI 0.45-0.97),双侧p=0.035。
- 扩展通路改变亚组共76例(占意向治疗人群54%):卡匹色替组(n=39)中位无进展生存12.8个月(95%CI 6.6-18.8) vs 安慰剂组(n=37)4.6个月(95%CI 2.8-7.9),校正HR 0.44(95%CI 0.26-0.72),双侧p=0.0014。
- 扩展通路改变亚组中位总生存:卡匹色替组38.9个月(95%CI 23.3-50.7) vs 安慰剂组20.0个月(95%CI 14.8-31.4),校正HR 0.46(95%CI 0.27-0.79),双侧p=0.0047。
- 扩展通路未改变亚组中,卡匹色替组(n=30)与安慰剂组(n=34)的无进展生存和总生存均无统计学显著差异。
关键数值与推荐
- 卡匹色替组在主要分析后新增1例严重不良事件(肺炎)。
- 1例死亡(非典型肺部感染)被评估为可能与卡匹色替治疗相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要3期数据来证实这些结果,包括FAKTION试验未纳入的既往CDK4/6抑制剂暴露患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Capivasertib, an AKT inhibitor, added to fulvestrant, was previously reported to improve progression-free survival in women with aromatase inhibitor-resistant oestrogen receptor (ER)-positive, HER2-negative advanced breast cancer. The benefit appeared to be independent of the phosphoinositide 3-kinase (PI3K)/AKT/phosphatase and tensin homologue (PTEN) pathway alteration status of tumours, as ascertained using assays available at the time. Here, we report updated progression-free survival and overall survival results, and a prespecified examination of the effect of PI3K/AKT/PTEN pathway alterations identified by an expanded genetic testing panel on treatment outcomes. METHODS: This randomised, multicentre, double-blind, placebo-controlled, phase 2 trial recruited postmenopausal adult women aged at least 18 years with ER-positive, HER2-negative, metastatic or locally advanced inoperable breast cancer and an Eastern Cooperative Oncology Group performance status of 0-2, who had relapsed or progressed on an aromatase inhibitor, from across 19 hospitals in the UK. Participants were randomly assigned (1:1) to receive intramuscular fulvestrant 500 mg (day 1) every 28 days (plus a 500 mg loading dose on day 15 of cycle 1) with either capivasertib 400 mg or matching placebo, orally twice daily on an intermittent weekly schedule of 4 days on and 3 days off, starting on cycle 1 day 15. Treatment continued until disease progression, unacceptable toxicity, loss to follow-up, or withdrawal of consent. Treatment was allocated by an interactive web-response system using a minimisation method (with a 20% random element) and the following minimisation factors: measurable or non-measurable disease, primary or secondary aromatase inhibitor resistance, PIK3CA status, and PTEN status. The primary endpoint was progression-free survival in the intention-to-treat population. Secondary endpoints shown in this Article were overall survival and safety in the intention-to-treat population, and the effect of tumour PI3K/AKT/PTEN pathway status identified by an expanded testing panel that included next-generation sequencing assays. Recruitment is complete. The trial is registered with ClinicalTrials.gov, number NCT01992952. FINDINGS: Between March 16, 2015, and March 6, 2018, 183 participants were screened for eligibility and 140 (77%) were randomly assigned to receive fulvestrant plus capivasertib (n=69) or fulvestrant plus placebo (n=71). Median follow-up at the data cut-off of Nov 25, 2021, was 58·5 months (IQR 45·9-64·1) for participants treated with fulvestrant plus capivasertib and 62·3 months (IQR 62·1-70·3) for fulvestrant plus placebo. Updated median progression-free survival was 10·3 months (95% CI 5·0-13·4) in the group receiving fulvestrant plus capivasertib compared with 4·8 months (3·1-7·9) for fulvestrant plus placebo (adjusted hazard ratio [HR] 0·56 [95% CI 0·38-0·81]; two-sided p=0·0023). Median overall survival in the capivasertib versus placebo groups was 29·3 months (95% CI 23·7-39·0) versus 23·4 months (18·7-32·7; adjusted HR 0·66 [95% CI 0·45-0·97]; two-sided p=0·035). The expanded biomarker panel identified an expanded pathway-altered subgroup that contained 76 participants (54% of the intention-to-treat population). Median progression-free survival in the expanded pathway-altered subgroup for participants receiving capivasertib (n=39) was 12·8 months (95% CI 6·6-18·8) compared with 4·6 months (2·8-7·9) in the placebo group (n=37; adjusted HR 0·44 [95% CI 0·26-0·72]; two-sided p=0·0014). Median overall survival for the expanded pathway-altered subgroup receiving capivasertib was 38·9 months (95% CI 23·3-50·7) compared with 20·0 months (14·8-31·4) for those receiving placebo (adjusted HR 0·46 [95% CI 0·27-0·79]; two-sided p=0·0047). By contrast, there were no statistically significant differences in progression-free or overall survival in the expanded pathway non-altered subgroup treated with capivasertib (n=30) versus placebo (n=34). One additional serious adverse event (pneumonia) in the capivasertib group had occurred subsequent to the primary analysis. One death, due to atypical pulmonary infection, was assessed as possibly related to capivasertib treatment. INTERPRETATION: Updated FAKTION data showed that capivasertib addition to fulvestrant extends the survival of participants with aromatase inhibitor-resistant ER-positive, HER2-negative advanced breast cancer. The expanded biomarker testing suggested that capivasertib predominantly benefits patients with PI3K/AKT/PTEN pathway-altered tumours. Phase 3 data are needed to substantiate the results, including in patients with previous CDK4/6 inhibitor exposure who were not included in the FAKTION trial. FUNDING: AstraZeneca and Cancer Research UK.
引用
- Howell SJ, Casbard A, Carucci M, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. Lancet Oncol. 2022. PMID: 35671774. doi:10.1016/S1470-2045(22)00284-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。